Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models

Evofosfamide (TH-302) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide. In hypoxic conditions Br-IPM is released and alkylates DNA. Ifosfamide is a chloro-isophosphoramide prodrug activated by hepatic Cytochrome P450 enzymes. Both compounds are used for the treatment of cancer....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Biol Ther
Autori principali: Sun, Jessica D., Liu, Qian, Ahluwalia, Dharmendra, Ferraro, Damien J., Wang, Yan, Jung, Don, Matteucci, Mark D., Hart, Charles P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5036787/
https://ncbi.nlm.nih.gov/pubmed/26818215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1139268
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi